Outlook Therapeutics, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended September 30, 2023. This is an annual filing; the provided text does not report standalone fourth-quarter results. The company is a pre-commercial biopharmaceutical company whose sole active development candidate is ONS-5010 (LYTENAVA, bevacizumab-vikg), an investigational ophthalmic treatment for retinal diseases.
Financial performance and position
| Metric | FY2023 / September 30, 2023 | FY2022 / September 30, 2022 |
|---|---|---|
| Product revenue | None | None |
| Research and development expense | $26.5 million | $42.3 million |
| General and administrative expense | $26.7 million | $20.7 million |
| Operating loss | $53.1 million | $63.1 million |
| Net loss | $59.0 million; $0.24 per share | $66.1 million; $0.31 per share |
| Cash used in operating activities | $43.0 million | $56.7 million |
| Cash and cash equivalents | $23.4 million | $17.4 million |
| Current liabilities | $46.7 million | $19.7 million |
| Debt, current carrying value | $35.6 million | $10.9 million |
| Total assets / stockholders’ equity (deficit) | $32.3 million / $(14.4) million | $28.5 million / $8.7 million |
Margins are not meaningful because the company has not generated product sales. Financing activities provided $49.0 million of cash in FY2023, primarily from equity offerings and the December 2022 convertible note. No clear product-sales or operating profitability outlook is provided.
Changes versus FY2022
- Net loss narrowed by $7.1 million and operating cash use fell by $13.7 million.
- R&D expense declined by $15.9 million. The company cites, among other factors, a $6.2 million FDA BLA fee paid in the prior period that was waived and refunded in FY2023, lower ONS-5010 development costs, and lower stock-based compensation.
- G&A expense rose by $5.9 million, primarily from higher professional fees for anticipated pre-launch preparations.
- Current liabilities rose substantially, primarily reflecting the convertible note. Common shares outstanding increased from 227.3 million to 260.3 million during the fiscal year.
Outlook, risks and notable items
- FDA and clinical development: The FDA issued a Complete Response Letter on August 29, 2023, citing chemistry, manufacturing and controls issues, open pre-approval inspection observations, and insufficient substantial evidence. After FDA meetings, the company said an additional adequate and well-controlled trial and further CMC information are required for a wet AMD BLA resubmission.
- NORSE EIGHT: The company submitted a Special Protocol Assessment in December 2023 for a planned randomized trial of approximately 400 patients; enrollment was expected to begin in early 2024, with an FDA response to the SPA expected in early February 2024. Trial costs were still being assessed, and additional funding was needed.
- International outlook: The EMA review of the ONS-5010 application was advanced, with a decision estimated for the first half of calendar 2024. This is an estimate, not an approval.
- Liquidity and going concern: Management and the auditor identified substantial doubt about the company’s ability to continue as a going concern. Management said the $23.4 million cash balance was not sufficient to fund operations for one year from the filing date, considering NORSE EIGHT costs and debt maturity. Management estimated cash could fund operations through June 2024 excluding NORSE EIGHT costs and repayment of the note. Additional capital or a successful note extension is needed; neither is assured.
- Debt: The December 2022 unsecured convertible note carried a 9.5% interest rate. Its maturity was extended in December 2023 to April 1, 2024 for a $475,000 fee; further extension discussions were ongoing. Default provisions can increase the balance, accelerate repayment and raise interest to 22%. Financing or conversion may materially dilute shareholders.
- Commercialization and execution: The company plans a U.S. launch itself if approved and has a Cencora distribution and services arrangement. It has no existing sales and marketing organization. Regulatory approval, adequate funding, manufacturing readiness, reimbursement, physician uptake and competition remain significant uncertainties. Management cited potential product revenue as early as late 2025, contingent on successful development, approval and launch.
- Legal and listing risks: A securities class action filed in November 2023 alleges misleading statements about the BLA; the company could not estimate potential costs and had established no reserve. The company also received a Nasdaq minimum-bid-price deficiency notice, with an April 15, 2024 compliance date.
- Audit and controls: The auditor issued an unqualified opinion on the financial statements but highlighted the going-concern uncertainty. Management concluded disclosure controls and internal control over financial reporting were effective; the auditor was not required to attest to internal-control effectiveness.
Key facts investors should verify
- FDA feedback, the NORSE EIGHT SPA response, trial start, enrollment pace, costs and results, and progress addressing the CRL’s CMC and inspection issues.
- EMA review outcome and timing, and whether any approval would carry conditions or differ from the company’s expectations.
- Cash runway, near-term financing plans, note repayment or further extension terms, and potential dilution or default consequences.
- Manufacturing readiness and supply arrangements, including whether inspection observations have been resolved.
- Status and potential financial exposure of the securities class action and Nasdaq listing compliance.
- Whether commercial infrastructure, reimbursement access, pricing and market adoption support the company’s launch and revenue assumptions.